Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
brief summary
This phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors. The study is designed to assess clinical efficacy and safety, building on a strong synergistic rationale and promising early-phase data.
detailed description
Given the substantial unmet medical need for effective treatment options in patients with advanced refractory solid tumors, and grounded in the synergistic rationale of combining EGFR-targeted therapy with immune checkpoint modulation, the encouraging efficacy and manageable safety profiles observed in early phase studies of Becotatug Vedotin (MRG003) andPucotenlimab (HX008) provide a strong rationale for further investigation. Accordingly, a methodologically rigorous phase II clinical trial is warranted to objectively evaluate the clinical efficacy and safety of this dual regimen specifically in patients with high EGFR expressing advanced refractory solid tumors.
official title
ELEVATE Study: A Phase II Single-Arm Open-Label Single-Center Exploratory Trial of Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Advanced Refractory Solid Tumors With EGFR-Positive